Objective: The aim of the study was to describe the presentation and successful treatment of labial fusion in women after allogeneic hematopoietic cell transplantation (HCT).
V
ulvovaginal chronic graft-versus-host-disease (cGvHD) is an important yet underrecognized site of cGvHD that affects more than a quarter of women who survive after allogeneic hematopoietic stem cell transplantation. 1 Labial fusion, a rare form of vulvovaginal cGvHD, may also be seen in other settings such as lichen planus (LP) and lichen sclerosis (LS). 2 Labial fusion may compromise quality of life because of difficulties with urination and dyspareunia. We describe the successful treatment of 5 cases of labial fusion occurring after matched allogeneic peripheral blood hematopoietic cell transplantation (HCT).
MATERIALS AND METHODS
Women with labial fusion were prospectively identified while participating in a National Institutes of Health intramural clinical trial that included assessment of genital cGvHD. Clinical data were collected regarding underlying disease, transplant regimen, time of labial fusion diagnosis post-HCT, genital symptoms, systemic sites of cGvHD and treatment, and follow-up. All patients had labial fusion that was lysed under general anesthesia (case 1) or an outpatient setting following the steps in Table 1 (all other cases). Topical skin adhesive (Dermabond) was applied to the denuded labial surfaces to maintain labial separation during healing (see Figure 1C ). Consent for publication was obtained from all patients. Each author was an employee in the National Institutes of Health Intramural Research Program.
RESULTS
At presentation with labial fusion 23-months to 8-years post-HCT, women ranged in age from 35 to 50 years. Clinical details are presented in Table 2 . Four of the 5 patients had active cGvHD; 3 patients had severe sclerotic cGvHD, and 1 patient had bronchiolitis obliterans. One patient with rheumatoid arthritis had no sites of cGvHD and had recently stopped taking etanercept. On followup, all women were significantly improved and, in the 2 women who were sexually active, dyspareunia resolved.
Case 1
Within 1 year after HCT, case 1 developed severe cGvHD including esophageal strictures, oral stenosis, and trismus. Concurrent vulvovaginal cGvHD was treated with topical clobetasol and estrogen, then topical tacrolimus. Five-years posttransplant, she developed labial fusion and vaginal scarring. At surgery, labial fusion was treated, but lysis of vaginal adhesions was not undertaken.
By 8-years posttransplant, case 1 had managed her extensive systemic cGvHD with tacrolimus and sirolimus, more than 75 extracorporeal photophoresis treatments, 31 esophageal dilatations, and steroids. Esophageal cGvHD restricted her oral intake and a percutaneous endoscopic gastrostomy tube provided her nutrition.
Case 1 presented with worsening difficulty with micturition, vulvar fullness, and inability to have intercourse; she had only a pinpoint opening for passage of urine (see Figure 2A) . Her complete labial fusion and vaginal adhesions were lysed under general anesthesia (see Figure 2B) , and conjugated estrogen cream was placed in the vagina. One month later, some labial reagglutination and vaginal scarring had occurred (see Figure 2C ). 
Case 2
After HCT, case 2 developed ocular and vulvar cGvHD while immunosuppression was tapered. She was later diagnosed with bronchiolitis obliterans. With care from both a gynecologist and dermatologist, she was given oral contraceptive pills that were stopped after 7 months for elevated liver function tests, a topical antifungal medication, estradiol vaginal tablets, topical clobetasol, and compounded estrogen.
At 28 months after transplant, case 2 presented with vaginal dryness and dyspareunia. Labial fusion was not observed on initial examination but was noted with spreading the labia (see Figures 1A , B) and was easily lysed (see Table 1 , Figure 1C ). On examination 2 months later, her labial fusion and dyspareunia resolved.
Case 3
One year after HCT, case 3 developed sclerotic chronic GvHD, which became progressive over her body. Approximately 2-years posttransplant, she presented with vulvar fullness, dyspareunia, and vulvar scarring. Labial fusion was lysed in the outpatient clinic. On examination 1 year later, her labial fusion and dyspareunia were resolved.
Case 4
After HCT, case 4 developed liver cGvHD and was treated with extracorporeal photopheresis. She later developed focal sclerodermic changes, which became extensive and ocular cGvHD treated with Boston scleral lens. Five-years post-HCT, she developed severe vulvovaginal GvHD with vagina scarring for which she used dilators with topical clobetasol and estrogen. On presentation, her labia minora were resorbed causing some vulvar distortion, and the labia minora were fused below the clitoris to the urethral opening. Labial fusion was lysed in the outpatient clinic. On examination for several months, the labial fusion remained resolved.
Case 5
In contrast to cases 1 to 4, case 5 did not have any history of nongynecologic sites of cGvHD and was maintained on low-dose immunosuppression. Four years after HCT, case 5 presented with labial fusion above the urethra to the base of the clitoris and arcuate vaginal scarring. She had rheumatoid arthritis and had recently stopped taking etanercept. She was currently not sexually active and was unaware of her gynecological findings. Case 5 refused to undergo biopsy to distinguish vulvovaginal GvHD from LS or LP but did consent to have these adhesions lysed in the outpatient clinic. On follow-up, the labial adhesions were improved.
DISCUSSION
Labial fusion is recognized as a rare form of vulvovaginal cGvHD 3 with the potential to interfere with voiding, preventing sexual intimacy, and impairing overall quality of life. One patient presented with complete labial fusion, which significantly affected micturition and required expeditious surgical intervention. The other patients had labial fusion that might be overlooked on physical examination because it occurred in the area above the urethra. Nonetheless, this labial fusion significantly narrowed the introitus but did not compromise urination and resulted in dyspareunia After the labia heal, a pea-sized amount of topical clobetasol ointment and a half inch of topical conjugated estrogen cream were applied to the affected area by the patient daily for several weeks to prevent reagglutination. When the mucosa was no longer inflamed and appeared normal, usually approximately 4 to 6 weeks, the patient tapered and then stopped treatment. HCT indicates hematopoietic cell transplantation; GvHD, graft-versus-host-disease; TBI, total body irradiation.
among those who were sexually active. In these other patients, diagnosis and an office procedure combined with local medical therapy resolved dyspareunia and improved their clinical findings. These cases of labial fusion all occurred in women post-HCT, and 4 of the 5 cases occurred in the setting of other severe cGvHD, mostly sclerotic cGvHD. We had previously reported an association between severe genital cGvHD, usually vaginal scarring, and sclerotic cGvHD. 4 However, other conditions besides cGvHD may be associated with labial fusion, as evidenced by case 5. This patient was without history, current signs, or symptoms of cGvHD before noting labial fusion on routine examination, a finding that had not been present on examination 1 year earlier. She had rheumatoid arthritis and had recently stopped using etanercept. In patients with autoimmune diseases as in her case, the diagnosis of LS or LP is possible. 5 The LS, LP, and cGvHD can cause vacuolization and separation of the basal layer of mucosal cells in the vulva that can lead to labial fusion, making it difficult to distinguish among these diagnoses either histologically or clinically. 6 Although biopsy might have aided in this diagnosis, treatment by lysing adhesions and using topical steroids and estrogen would be similar. Therefore, a patient's history and physical examination are important in considering the association of labial fusion with other diseases, such as cGvHD or other autoimmune diseases.
In addition to having severe sclerotic cGvHD and rheumatoid arthritis, these patients had other factors that are associated with labial fusion. All but case 5 were hypogonadal posttransplant. Development of labial fusion may be more common in hypoestrogenic females as seen in prepubescent girls. 1 Pelvic irradiation, commonly associated with scarring, was used in only 1 woman and thus does not seem to be an important factor in these cases.
More than a quarter of women who survive after allogeneic HCT develop vulvovaginal GvHD 1, 7 Vulvovaginal GvHD is more common in women receiving peripheral blood HCT compared with bone marrow transplantation and typically has an insidious presentation occurring weeks to as long as 8-year posttransplant. 4, 8, 9 The symptoms of vulvovaginal burning, irritation, dyspareunia, and signs of patchy erythematous inflammation and later ulceration are early clinical features of vulvar cGvHD. If left untreated, these symptoms may evolve to vulvar adhesions. 4, 9 In this cohort, labial adhesions developed despite previous systemic and sometimes local treatment with estrogen or immunosuppressive therapy. When detected early, an office procedure followed by topical medical therapy led to significant improvement in all patients.
Coordination of care among transplant physicians, gynecologists, and primary care providers is critical to recognizing and quickly treating any genital signs and symptoms. These patient histories highlight the importance of asking women who have undergone allogeneic HCT, especially those with severe cGvHD, about dyspareunia and pain with urination. Those with genital symptoms warrant referral to a gynecologist skilled in evaluation and treatment of women post-HCT. Labial fusion may be suspected by clinical symptoms but is easily recognized on pelvic examination. These cases illustrate that labial fusion after allogeneic HCT, if diagnosed early enough, may be treated successfully with an office procedure and medical therapy.
